# David Weber

> David Weber, PhD, is the President and CEO of Mosanna Therapeutics, a Redwood City biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea that aims to restore the body's natural airway reflex during sleep. A biotech operator with more than 30 years in drug development, capital formation, and corporate strategy, he previously led Otonomy through its IPO and multiple clinical programs, and served as CEO of MacuSight and Oculex Pharmaceuticals. He joined Mosanna in June 2025 as the company launched with an $80 million Series A.

- **Role:** President and CEO at Mosanna Therapeutics
- **Organizations:** Mosanna Therapeutics, Otonomy, MacuSight, Oculex Pharmaceuticals, Procter & Gamble, Oral-B Laboratories
- **Nationality:** American
- **Education:** PhD, Medical Microbiology, Creighton University School of Medicine, MS, Biological Sciences, Wichita State University, BS, Biological Sciences, Wichita State University
- **Known for:** Led Otonomy through a successful IPO and the advancement of multiple clinical-stage programs, Associated with FDA-approved products OTIPRIO and OZURDEX, As CEO of MacuSight, advanced a sustained-delivery formulation of sirolimus and secured a strategic Asia licensing deal

## Career timeline

- **1990** — Began his career as a Senior Scientist in Healthcare Product Development at Procter & Gamble (Oral-B Laboratories)
- **2001** — Served as Acting CEO and EVP at Oculex Pharmaceuticals, work tied to the ophthalmic implant later known as OZURDEX
- **2004** — Became President and CEO of MacuSight, advancing a sustained-delivery sirolimus formulation for ophthalmic disease
- **2010** — Appointed President and CEO of Otonomy, leading its IPO and multiple clinical-stage programs including OTIPRIO
- **2025** — Named President and CEO of Mosanna Therapeutics and joined its Board of Directors as the company launched with an $80M Series A

## Achievements

- Led Otonomy through a successful IPO and the advancement of multiple clinical-stage programs
- Associated with FDA-approved products OTIPRIO and OZURDEX
- As CEO of MacuSight, advanced a sustained-delivery formulation of sirolimus and secured a strategic Asia licensing deal
- Launched Mosanna Therapeutics with an $80 million Series A in June 2025
- More than 30 years of experience across drug development, capital formation, and corporate strategy

## Latest updates

- **2025-06** — Appointed President and CEO of Mosanna Therapeutics and joined the Board as the company launched with an $80 million Series A led by EQT Life Sciences and Pivotal bioVenture Partners.

## Links

- Website: https://mosanna.com
- LinkedIn: https://www.linkedin.com/in/david-weber-phd-227b089/

---

Profile page: https://yespress.io/david-weber
Published by YesPress — https://yespress.io
Last updated: 2026-07-20